HC Wainwright & Co. Maintains Buy on Inhibrx Biosciences, Lowers Price Target to $220
Inhibrx Reports Third Quarter 2026 Financial Results
Inhibrx Biosciences Files Shelf Prospectus For Offering; Size Not Disclosed
Inhibrx Biosciences (INBX) Stock Looks Hard To Pin Down At This Price
Are Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility?
Inhibrx Announces Participation in Upcoming Scientific Conferences
Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
Inhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp Rerating
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom
Inhibrx Shares Rise After Positive Phase 2 Head and Neck Cancer Data
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
Inhibrx To Present Phase 2 INBRX-106 HNSCC Results On Webcast Live On Tuesday, September 8 At 5:00 a.m. PT
HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245
Inhibrx Reports Second Quarter 2026 Financial Results
Inhibrx Biosciences: The Whole Story Rides On INBRX-106
Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.